Recent Updates
Recently added Catalysts

Bepreve

Phase 3

Allergic Conjunctivitis | Small molecule | Other |Bausch + Lomb Corporation|Last Updated: Feb 15, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment861
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00586625Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal VolunteersPHASE3 COMPLETED 861Oct 1, 2007 -Feb 15, 2013 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Ocular Comfort
Day 8 & Day 22

A 4-step grading scale with half unit (1-step) increments allowed: 0=Comfortable;discomfort absent; 1.0=Generally comfortable; mild discomfort; 2.0=Some discomfort but tolerable; moderate comfort; 3.0=Severely uncomfortable or intolerable

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
BepreveEXPERIMENTALbepotastine besilate ophthalmic solution 1.5%
PlaceboPLACEBO_COMPARATORvehicle
Interventions
NameTypeDescription
BepreveDRUGOne drop, both eyes, twice a day
PlaceboDRUGOne drop, both eyes, twice a day
Unlock Study Design Details
Eligibility Criteria
Age Range3 Years — N/A
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Subjects must be at least 3 years of age, and have ocular health within normal limits Exclusion Criteria: * No active ocular disease

Unlock Eligibility Criteria